NEJM :ANGPTL3反义寡核苷酸对心血管以及代谢有何影响?

2017-07-20 MedSci MedSci原创

近日,在医学权威杂志The NEW ENGLAND JOURNAL of MEDICINE上发表了一篇研究文章,研究人员旨在探讨ANGPTL3反义寡核苷酸对心血管以及代谢的影响。流行病学和基因组关联研究法将ANGPTL3的功能失活变异、编码血管生成素样蛋白3与低水平的血浆脂蛋白联系起来。

近日,在医学权威杂志The New England Journal of Medicine上发表了一篇研究文章,研究人员旨在探讨ANGPTL3反义寡核苷酸对心血管以及代谢的影响。

背景:
流行病学和基因组关联研究法将ANGPTL3的功能失活变异、编码血管生成素样蛋白3与低水平的血浆脂蛋白联系起来。

方法:
研究人员评估了小鼠的反义寡核苷酸(ASOs)对血浆脂质水平、甘油三酯清除、肝甘油三酯含量、胰岛素敏感性和动脉粥样硬化的影响,以Angptl3信使RNA(mRNA)作为目标。随后,研究人员又纳入了44名人类参与者,他们的甘油三酸酯水平为90到150mg/dL(1.0到1.7mmol/L)或0mg/dL,取决于剂量组。这些研究对象被随机分配接受皮下注射安慰剂或反义寡核苷酸针对于ANGPTL3 mRNA,分为单一剂量组(20、40或80mg)或多个剂量组(10、20、40或60mg/周,共6周)。主要观察终点为安全性、副作用、药物动力学和药效学措施,以及脂类和脂蛋白水平的变化。

结果:
小鼠经过治疗使肝脏的ANGPTL3 mRNA、ANGPTL3 蛋白、甘油三酯和低密度脂蛋白(LDL)胆固醇水平降低,以及肝甘油三酯含量降低和动脉粥样硬化恶化以及胰岛素敏感性增加。人类多剂量组经治疗6周后,ANGPTL3蛋白质的含量减少(减少了基线水平的46.6至84.5%,所有剂量组vs.安慰剂P <0.01),甘油三酯的水平也降低了33.2至63.1%,低密度脂蛋白胆固醇降低了1.3 - 32.9%,极低密度脂蛋白胆固醇降低了27.9 - 60.0%,非高密度脂蛋白胆固醇降低了10.0 - 36.6%,载脂蛋白B降低了3.4 - 25.7%以及载脂蛋白C-III降低了18.9 - 58.8%。其中,接受了反义寡核苷酸治疗的三名受试者和接受安慰剂的三名受试者报告称头晕或头痛。此研究没有严重的不良事件。

结论:
由此可见,以小鼠ANGPTL3为目标的反义寡核苷酸(ASOs)可使动脉粥样硬化进展变得迟缓,并且降低了动脉粥样硬化性脂蛋白的水平。使用同样的策略以人类ANGPTL3为目标,降低了人类的动脉粥样硬化性脂蛋白的水平。

原始出处
Mark J. Graham, Richard G. Lee, Teresa A. Brandt,et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. NEJM. 2017 July. doi: 10.1056/NEJMoa1701329

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700412, encodeId=03911e0041205, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 26 08:28:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945613, encodeId=6f841945613fd, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Mar 31 22:28:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575367, encodeId=ab6e15e53673b, content=<a href='/topic/show?id=03753e66414' target=_blank style='color:#2F92EE;'>#反义寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37664, encryptionId=03753e66414, topicName=反义寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc816121587, createdName=fyxzlh, createdTime=Sat Jul 22 06:28:00 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700412, encodeId=03911e0041205, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 26 08:28:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945613, encodeId=6f841945613fd, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Mar 31 22:28:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575367, encodeId=ab6e15e53673b, content=<a href='/topic/show?id=03753e66414' target=_blank style='color:#2F92EE;'>#反义寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37664, encryptionId=03753e66414, topicName=反义寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc816121587, createdName=fyxzlh, createdTime=Sat Jul 22 06:28:00 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2018-03-31 xsm918
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700412, encodeId=03911e0041205, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 26 08:28:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945613, encodeId=6f841945613fd, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Mar 31 22:28:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575367, encodeId=ab6e15e53673b, content=<a href='/topic/show?id=03753e66414' target=_blank style='color:#2F92EE;'>#反义寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37664, encryptionId=03753e66414, topicName=反义寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc816121587, createdName=fyxzlh, createdTime=Sat Jul 22 06:28:00 CST 2017, time=2017-07-22, status=1, ipAttribution=)]

相关资讯

JCEM:血管生成素样蛋白3对血浆脂蛋白水平的影响

血管生成素样蛋白3(angiopoietin-like protein 3,ANGPTL3)是血管生成素和血管生成素样蛋白家族成员,因其与该家族成员有共同的结构特征而得名,即氨基端与分泌相关的信号肽,介导同源寡聚体形成的螺旋样结构域,一段短的连接肽和羧基端介导配体活性的纤维蛋白原样结构域。ANGPTL3是一种分泌蛋白,其mRNA主要在人、鼠的肝脏表达。既往研究表明angptl 3的生物学效应表现在

NEJM:ANGPTL3与冠心病风险

研究表明ANGPTL3基因突变或抑制与人体主要脂质组分减少和动脉粥样硬化性心血管疾病发病率降低相关

NEJM:Angptl3 反义寡核苷酸与血脂异常

在小鼠模型和患者中,针对Angptl3 基因的反义寡核苷酸可显著减少导致动脉粥样化的脂蛋白水平